AzurRx BioPharma Launches Phase 2 Trial Testing MS1819-SD Combined With PERT for EPI
AzurRx BioPharma has initiated a Phase 2 clinical trial testing its oral capsule MS1819-SD, combined with standard porcine pancreatic enzyme replacement therapy (PERT), in people with cystic fibrosis (CF) who have exocrine pancreatic insufficiency (EPI). PERT is the standard of care for EPI associated with…